Ono Pharmaceutical

Ono Pharmaceutical (JP), a leader in Pharmaceutical Preparation Manufacturing, is actively engaged in reducing its carbon footprint. For the reporting year 2024, the company reported total emissions of approximately 13.4 million kg CO2e, comprising Scope 1 emissions of about 7.7 million kg CO2e and Scope 2 emissions of approximately 1.2 million kg CO2e. Scope 3 emissions for the same year amounted to about 4.5 million kg CO2e, with key contributors including business travel (4.8 million kg CO2e) and fuel and energy-related activities (3 million kg CO2e). In 2023, Ono Pharmaceutical's total emissions were approximately 118.0 million kg CO2e, with Scope 1 at 6.7 million kg CO2e, Scope 2 at 9.4 million kg CO2e, and substantial Scope 3 emissions of 101.9 million kg CO2e, largely driven by purchased goods and services (64 million kg CO2e).

Ono Pharmaceutical has set ambitious climate targets. The company is working towards achieving carbon neutrality for its own emissions (Scope 1 and 2) by 2025, with an updated long-term goal of zero greenhouse gas emissions by 2035, advanced from the previous 2050 target. Furthermore, Ono Pharmaceutical has committed to a Science Based Targets initiative (SBTi) target to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 55% by FY2030 and achieve net zero emissions by FY2050, based on a FY2017 baseline. They also aim for a 30% reduction in absolute Scope 3 GHG emissions by FY2030 and a 60% reduction by FY2050 from the same baseline year. Reports indicate these near-term targets are currently on track.